Clinical Trial Detail

NCT ID NCT03629756
Title A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Arcus Biosciences, Inc.
Indications

ovarian cancer

Merkel cell carcinoma

renal cell carcinoma

endometrial cancer

lung non-small cell carcinoma

breast cancer

stomach cancer

colorectal cancer

clear cell renal cell carcinoma

melanoma

urinary bladder cancer

esophageal cancer

head and neck squamous cell carcinoma

Therapies

AB928 + GLS-010

Age Groups: adult senior

No variant requirements are available.